Bionomics is an Australian clinical-stage biopharmaceutical company specializing in the discovery and development of treatments for central nervous system (CNS) disorders. Founded in 1994 and headquartered in Adelaide, South Australia, Bionomics applies its proprietary ion channel modulation platform to identify and optimize small molecules that target key neurobiological pathways. The company’s research efforts focus on addressing unmet medical needs in anxiety, post-traumatic stress disorder (PTSD), cognition in schizophrenia and other neurological conditions.
Bionomics’ lead clinical candidate, BNC210, is a novel anxiolytic compound that modulates the alpha-7 nicotinic acetylcholine receptor to reduce anxiety without the sedative effects associated with traditional treatments. The company’s pipeline also includes BNC375, a potent allosteric enhancer of the AMPA receptor designed to improve cognitive function in patients with schizophrenia. Earlier-stage programs are advancing through preclinical studies in neurodegenerative and pain indications, leveraging Bionomics’ expertise in modulating ion channels and neurotransmitter systems.
In addition to its in-house research and development activities, Bionomics collaborates with academic institutions and strategic partners across North America, Europe and the Asia-Pacific region to accelerate clinical programs and expand its therapeutic reach. The company maintains research facilities in Adelaide and a presence in the United States to support regulatory interactions and clinical trial operations. Bionomics has secured funding through public listings on the Australian Securities Exchange as well as partnerships and grants to support its pipeline advancement.
Under the direction of an experienced management team and scientific advisory board, Bionomics continues to refine its drug discovery platform and advance its most promising candidates through clinical development. With a focus on CNS disorders that pose significant challenges for patients and healthcare systems, the company aims to bring innovative therapies to market that improve patient outcomes and quality of life.
AI Generated. May Contain Errors.
Free BNOEF Stock Alerts